No Data
No Data
Express News | Watching CervoMed; Shares Spike Higher, Traders Circulate Newsletter Mention
JonesTrading Maintains CervoMed(CRVO.US) With Buy Rating, Maintains Target Price $15
CervoMed's Promising Data and Phase 3 Prospects Boost Buy Rating
CervoMed Reports Positive Phase 2b Trial Results
Top 10 Russell 2000 Weekly Gainers and Losers as Wall Street Crashes
11 Health Care Stocks Moving In Thursday's Intraday Session